Various members of the Ets multigene family exhibit diverse roles in development, cell dierentiation, tissuespeci®c gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression signi®cantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.
Various members of the Ets multigene family exhibit diverse roles in development, cell dierentiation, tissuespeci®c gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression signi®cantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression. Oncogene (2002) 21, 3934 ± 3938. DOI: 10.1038/sj/ onc/1205503 Keywords: ErbB2; ESX; breast cancer; Ets ESX was ®rst identi®ed through an EST database for Ets factors involved in human mammary gland development and breast cancer and shows a unique epithelial-restricted pattern of expression (Chang et al., 1997) . ESX is restricted to tissues of epithelial origin (Chang et al., 1997; Tymms et al., 1997) such as the most dierentiated layer of the epidermis (Andreoli et al., 1997; Brembeck et al., 2000) and dierentiated mouse corneal epithelium (Yoshida et al., 2000) . ESX is also induced during mouse embryonic development as early as E7 and is associated with mammary gland development and terminal dierentiation of mammary epithelial cells (Neve et al., 1998) . Targeted disruption of ESX results in fetal lethality, abnormal intestinal morphogenesis and epithelial dierentiation (Ng et al., 2002) . Expression (cDNA) microarray analysis identi®ed ESX as one of only 16 genes (from a Unigene set of 25 000) up-regulated at least 10-fold during early stages of human ovarian tumorigenesis (Shridhar et al., 2001) . Interestingly, induction of ESX expression has also been demonstrated in non-epithelial cell lineages in response to in¯ammatory cytokines and lipopolysaccharides (LPS) (Rudders et al., 2000) , suggesting that ESX up-regulation may also play a role in mediating some in¯ammatory responses. However, little is known about the mechanistic up-regulation of ESX transcription and protein expression.
Previously, we postulated the existence of an integral relationship between ESX and ErbB2 expression (Chang et al., 1997) . While it was suggested that ESX might be able to transactivate the ErbB2 promoter, ESX and ErbB2 were also found coexpressed in a number of breast cancer cell lines. Furthermore the characterization of a functional ESX proximal promoter element revealed a number of potential transcription factor binding sites (Neve et al., 1998; Oettgen et al., 1999) . Basal activity of the murine ESX (mESX) promoter is positively regulated by serum stimulation and the EGF-family ligands NDF and EGF (Neve et al., 1998) . This raised the possibility that increases in ESX transcription may not only contribute to but also result from ErbB2 overexpression. Here we further characterize the regulation of ESX transcription and protein expression and provide evidence that the ESX promoter is a downstream target of the ErbB2 receptor tyrosine kinase.
Earlier we reported a sparse genomic map of *11 kb of the human ESX (hESX) locus (Chang et al., 1999) and partial analysis of the hESX proximal promoter (Neve et al., 1998) . We have now isolated 8 kb of mouse genomic DNA encompassing the entire mESX gene including *3 kb of upstream sequence. Comparison of the sequences revealed good homology between the human and mouse proximal promoter and exon sequences. In addition to the ESX proximal promoter region, other cis-acting elements are likely to be present in the upstream sequence that may exert control over hESX transcription. Therefore, in order to facilitate an accurate analysis of the hESX promoter, a construct encompassing approximately three kilobases of upstream sequence was cloned upstream of the luciferase reporter gene (termed 72872+519Luc). In Sk-Br-3 cells 72872+519Luc and the equivalent mouse promoter (mESXP) exhibited robust activity in contrast to the control vector ( Figure 1a ). The hESX construct was used in all subsequent experiments.
To test the ®delity of the ESX promoter construct, we transiently transfected 72872+519Luc into several cell lines that express varying levels of endogenous ESX. Co-transfection of a beta-galactosidase expression construct allowed comparison of transfection eciencies between the cell lines enabling us to directly compare the relative basal transcriptional activity of the hESX promoter in each cell line. We found that there was a good correlation between endogenous hESX expression and 72872+519Luc activity ( Figure  1b ). There was also a good correlation between the expression of ErbB2 and ESX, which supports a previous correlation between ESX and ErbB2 mRNA levels in various cancer cell lines (Chang et al., 1997) . These data suggest the promoter construct faithfully re¯ects endogenous ESX expression and supports the hypothesis that a biological relationship exists between ESX and ErbB2 expression.
Previously we reported that epidermal growth factor (EGF) and Neu Dierentiation factor (NDF) positively in¯uence mESX promoter activity. To further explore possible external regulators of hESX transcription we applied a variety of factors known to be associated with ErbB receptor signaling. Similar to the mESX promoter, EGF and NDF induced a stout four-and sixfold increase in hESX promoter activity respectively (Figure 2a ), which agrees with our published data showing an increase of ESX mRNA in response to NDF stimulation of Sk-Br-3 cells (Chang et al., 1997) .
The presence of a number of putative Ets binding sites in the ESX promoter suggested the potential for transcriptional regulation by Ets factors. In contrast to its ability to up-regulate ErbB2 transcriptional activity in the COS-7 cell line (Chang et al., 1997) , low levels of ectopically expressed HA-tagged ESX, in Sk-Br-3 and MCF-7 cells, had no eect on ESX promoter activity (Figure 2b ). At higher levels of expression ESX suppressed its own promoter possibly due to nonspeci®c`squelching' eects, as described previously (Figure 2b ) (Chang et al., 1999) . Moreover, expression of an ESX variant (ESX L143P ), which has a mutation in the acidic transactivation domain rendering it unable to bind the TATAA box binding protein (TBP) (Chang et al., 1999) had no eect on the ESX promoter ( Figure  2c ). Conversely, Elf-1, which positively transactivates the ErbB2 promoter in MCF-7 and Sk-Br-3 cells (Scott et al., 2000) , also increased ESX transcriptional activity (Figure 2c ) con®rming the potential for Ets regulation of the ESX promoter.
A preliminary ESX and ErbB2 Northern blot study of total RNA puri®ed from 11 dierent breast epithelial cell lines and seven dierent primary breast tumors suggested that overexpression of endogenous ESX transcripts correlates with overexpression of ErbB2 transcripts when samples were dichotymized into high (+) vs low (7) expressing subsets (ESX+/ErbB2+, n=7; ESX7/ErbB27, n=8; ESX+/ErbB27, n=3; ESX7/ErbB2+, n=0; w 2 =6.5, P=0.01) (Chang et al., 1997) . To verify this preliminary conclusion, a dierent Regions encompassing the upstream DNA to the site of translational initiation (72950+650/mESXP and 7 2872+519/ hESXP, from the murine and human sequences respectively) were cloned upstream of a luciferase reporter construct. Transient transfection of the murine and human ESX promoter constructs into the epithelial breast cancer cell line, Sk-Br-3, showed good basal activity (luciferase units) over control vector after 24 h transfection. (b) Transfection of the human ESX promoter into a number of epithelial (Sk-Br-3, MDA-MB-453, MCF-7, MCF12A, MCF10A, T47D and MDA-MB-435) and non-epithelial cell lines (K562) and human ®broblasts (hFib)) indicated that the isolated ESX promoter basal activity at 24 h faithfully re¯ects the levels of endogenous ESX in these cells. Western analysis shows a good correlation between ErbB2 and ESX protein levels. Methods: SkBr-3 human breast carcinoma cells were maintained in McCoys5A without tricine supplemented with 10% foetal calf serum (FCS). Transient transfections of all cell lines were carried out at least three times, in triplicate using Eectene transfection reagent (Qiagen) according to the manufacturer's instructions. Cells were grown in six-well plates and transfected at 50 to 60% con¯uency. In each well 1 mg of the luciferase reporter construct was cotransfected with 1 mg of SV40-LacZ (an internal control for transfection eciency). Cells were harvested after 24 h by washing once in PBS and lysing with luciferase assay reporter lysis buer (Promega). Luciferase assays were performed using the luciferase assay system (Promega) using a single-injector luminometer. bGalactosidase assays were performed with the Galactolight chemiluminescent system (Tropix) to normalise luciferase activity. Cells were lysed in NP40 lysis buer (50 mM HEPES pH 7.4, 1% NP40, 150 mM NaCl, 25 mM b-glycerol phosphate, 25 mM NaF, 5 mM EGTA, 1 mM EDTA, 10 mg/ml leupeptin and aprotinin, 1 mM PMSF) and cell debris was pelleted at 10 0006g for 30 min. Protein concentration was determined by the method of Bradford. Proteins were resolved on 4 ± 12% gradient SDS ± PAGE gels, blotted onto PVDF and detected by ECL. ESX and ErbB2 expression was visualised by Western analysis using primary antibodies to the ESX protein (rabbit polyclonal, Chang et al., 1999) and ErbB2 extracellular domain (c-neu monoclonal antibody Ab-2, Oncogene) respectively group of 45 unselected primary ductal breast cancers were analysed by quantitative RT ± PCR for both ESX and ErbB2 transcript levels, with ESX and ErbB2 results expressed relative to the housekeeping genes GUS (beta-glucuronidase) and GAPD (glyceraldehyde-3-phosphate dehydrogenase). As shown in Figure 3a , and without dichotymizing these study samples, ESX transcript levels show a statistically signi®cant positive correlation (Pearson) with ErbB2 transcript levels (P50.002). Consistent with the preliminary Northern blot study, breast tumors with the highest ErbB2 expression (ErbB2/GUS ratios 46.8) showed a higher median ESX expression level as compared to those with lower ErbB2 transcript levels.
Given this positive correlation between ErbB2 and ESX expression, we tested the eect of ectopic expression of ErbB2 on ESX promoter activity in a low-ErbB2 expressing cell line. Increasing amounts of ErbB2 cDNA were transiently co-transfected with 72872+519Luc into MCF-7 cells and luciferase activity measured after 48 h. In agreement with our previous observations, high ErbB2 expression was found to increase ESX promoter activity (Figure 2d ) providing direct evidence that the ErbB2 gene product aects ESX transcription.
Sk-Br-3 cells are dependent on ErbB2 for proliferation Neve et al., 2000) . Inhibition of ErbB2 receptor function by kinase inhibitors or receptor-targeted antibodies induces a G1 cell cycle arrest. Both mitogen-activated protein kinase (MAPK/ ERK) and phosphatidylinositol-3-kinase (PI3K) are key downstream mediators of ErbB2 stimulated cell cycling. Sk-Br-3 cells, transiently transfected with 72872+519Luc, were incubated for 4 h with inhibitors of the ErbB2 kinase (AG1478; 10 mm), MAPK (PD98059; 50 mm) or PI3K (LY294002; 50 mm). These inhibitors appreciably decreased ESX promoter activity after 4 h treatment (Figure 3b) . We next studied the eect of these inhibitors, after 4 h treatment, on endogenous ESX protein levels in Sk-Br-3 cells. These (AG1478), PI3K (LY 294002, LY) and MAPK (PD98059, PD), were tested for their eects after 4 h treatment on endogenous ESX expression (measured by Western analysis) and ESX promoter activity (measured using a transient promoter assay). Eectiveness of each inhibitor was determined by Western blotting using inhibitors for the phosphorylated forms of p44/42 MAPK, PKB (a downstream target of PI3K) (Cell Signalling) and ErbB2 (Upstate). ESX expression was decreased by inhibition of ErbB2 and PI3K, while no decrease was noted after treatment with the MAPK inhibitor. Protein loading was analysed by blotting with an ErbB2-antibody (Oncogene). Methods: Primary invasive ductal breast tumors (n=45), dissected immediately upon surgical resection to 470% tumor cell homogeneity, snap-frozen and cryobanked (liquid nitrogen) by the UCSF Comprehensive Cancer Center's Breast Oncology Program, were placed in Trizol reagent (Gibco ± BRL Life Technologies) for total RNA isolation according to the manufacturer's instructions and with the inclusion of a second Trizol extraction followed by resuspension in formamide and ®nal puri®cation on RNeasy columns (Qiagen). Reverse transcription (RT) reactions and real-time quantitative PCR (TaqMan 1 ) were performed as we have described previously (Albertson et al., 2000; Collins et al., 2001; Godfrey et al., 2000) . Transcript levels for a given gene, measured in replicate, were calculated as 2 7DcT where DcT is the dierence in the number of cycles for the¯uorescence intensity to reach a set threshold value; the mean values of replicate analyses were then expressed relative to the mean values for the two housekeeping genes, GUS (beta-glucuronidase) and GAPD (glyceraldehyde-3-phosphate dehydrogenase). TaqMan 1 linearity using the ABI Prism 7700 Sequence detection system spanned 5-logs of gene transcript levels, and reproducibility was validated for four genes from six tumor RNA samples analysed three times at three month intervals. PCR primer (forward, reverse) and¯uorogenic probe sequences designed using ABI Primer Express 1 software, chosen to amplify cross exonic junctions, and checked for speci®city by Blast searches were as previously described (Godfrey et al., 2000) and are indicated in (Figure 3b ). Incubation of Sk-Br-3 cells with AG1478 caused a reduction of both phospho-p44/42 MAPK and phospho-protein kinase B (PKB), a downstream target of the PI3K pathway, and signi®cantly reduced ESX protein levels. Treatment with LY294002 decreased ESX promoter activity and ESX protein levels, along with its expected decrease in phospho-PKB. In contrast PD 98059, which decreased phospho-p44/42 levels similar to that of AG1478 with little eect on phospho-PKB, had no inhibitory eect on either ESX promoter activity or protein levels (Figure 3b ). These data support earlier studies in Sk-Br-3 cells (Neve et al., 2001) showing the dominant eect of anti-ErbB2 antibodies on the PI3K/ PKB pathway in these cells and suggest that ErbB2-activated PI3K/PKB rather than MAPK signalling is responsible for ESX promoter upregulation. Known downstream targets of activated PI3K/PKB include inhibition of Forkhead transcription factors and activation of NF-kB (Khwaja, 1999) , introducing several possible ESX inducing mechanisms including up-regulation via the ESX proximal promoter's NF-kB response element (Neve et al., 1998) . Ets proteins have become the focus of intense interest recently given their roles in transcriptional regulation of both normal and tumourigenic processes.
Equal eorts have been applied to delineating the mechanisms through which oncogenes, such as ErbB2, act and the gene programs they regulate that lead to oncogenesis. Unfortunately, despite a wealth of information highlighting the importance of ErbB2 in human cancer, the fundamental mechanisms through which ErbB2 overexpression contributes to tumorigenesis remain poorly de®ned. Here we have used a number of approaches to provide evidence that ESX is an ErbB2-activated gene target and represents a key transcriptional mediator of ErbB2 signaling. While it is now clear that ESX transcript and protein levels are regulated through ErbB2-dependent pathways, it remains to be seen which ESX-regulated genes contribute to ErbB2-induced oncogenesis.
